Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.63 |
| ▸ | HRH1 | P35367 | 10/20 | 0.63 |
| ▸ | HRH2 | P25021 | 9/20 | 0.63 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244494 | 0.95 | HRH3 (0.66) | HRH3HRH1HRH2EGLN2XDH | |
| SCHEMBL1723767 | 0.91 | HRH3 (0.54) | HRH3HRH1HRH2EGLN2 | |
| SCHEMBL491704 | 0.87 | HRH3 (0.64) | HRH3HRH1HRH2EGLN2 | |
| SCHEMBL3564647 | 0.82 | MEN1 (0.48) | HRH3HRH1HRH2 | |
| SCHEMBL1715005 | 0.81 | HRH3 (0.91) | HRH3HRH1HRH2 | |
| SCHEMBL3558558 | 0.81 | SIGMAR1 (0.56) | HRH3HRH1HRH2 | |
| SCHEMBL3559203 | 0.81 | SIGMAR1 (0.56) | HRH3HRH1HRH2 | |
| SCHEMBL28826913 | 0.81 | HRH3 (0.53) | HRH3HRH1HRH2XDH | |
| SCHEMBL3564027 | 0.78 | CHEK1 (0.50) | — | |
| SCHEMBL3572835 | 0.77 | HRH3 (0.61) | HRH3HRH1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001066534-A2 | CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | HRH4, HRH2, HRH3 | HRH3 3/4885HRH1 4/4885HRH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.